NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Capricor Therapeutics Inc (NASDAQ: CAPR)

 
CAPR Technical Analysis
1
As on 2nd Mar 2026 CAPR STOCK Price closed @ 26.86 and we RECOMMEND N/A for LONG-TERM with Stoploss of 0.00 & N/A for SHORT-TERM with Stoploss of 0.00 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

CAPRSTOCK Price

Open 26.69 Change Price %
High 27.62 1 Day N/A N/A
Low 26.30 1 Week 0.00 0.00
Close 26.86 1 Month 0.00 0.00
Volume 669331 1 Year 0.00 0.00
52 Week High 0.00 | 52 Week Low 0.00
 
NASDAQ USA Most Active Stocks
LPTX 2.05 365.91%
AMRS 0.14 100.00%
WBA 11.98 0.50%
NVDA 182.48 %
ONDS 10.67 %
LMDX 0.02 0.00%
YGMZ 0.02 -66.67%
BHAT 0.04 %
PLUG 1.81 %
AAL 12.52 %
 
NASDAQ USA Top Gainers Stocks
MRIN 3450.00 383233.34%
MRIN 3450.00 383233.34%
SPNS 13950.00 32005.87%
SPNS 13950.00 32005.87%
AMRK 3526.00 11954.70%
AMRK 3526.00 11954.70%
KTRA 6.30 2763.64%
IDRA 8.64 1909.30%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
 
NASDAQ USA Top Losers Stocks
LEXXW 0.00 -100.00%
HTOOW 0.00 -100.00%
ARKOW 0.00 -100.00%
RELIW 0.00 -100.00%
FPAY 0.01 -94.74%
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
SWSSU 1.06 -89.40%
OTRK 0.07 -78.79%
CASI 0.21 -73.75%
 
 
CAPR
Daily Charts
CAPR
Intraday Charts
Whats New @
Bazaartrend
CAPR
Free Analysis
 
CAPR Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
 
CAPR Forecast March 2026
4th UP Forecast0
3rd UP Forecast0
2nd UP Forecast0
1st UP Forecast0
1st DOWN Forecast0
2nd DOWN Forecast0
3rd DOWN Forecast0
4th DOWN Forecast0
 
CAPR Weekly Forecast
4th UP Forecast0.00
3rd UP Forecast0.00
2nd UP Forecast0.00
1st UP Forecast0.00
1st DOWN Forecast0.00
2nd DOWN Forecast0.00
3rd DOWN Forecast0.00
4th DOWN Forecast0.00
 
CAPR Forecast2026
4th UP Forecast0
3rd UP Forecast0
2nd UP Forecast0
1st UP Forecast0
1st DOWN Forecast0
2nd DOWN Forecast0
3rd DOWN Forecast0
4th DOWN Forecast0
 
 
CAPR Other Details
Segment EQ
Market Capital 86793696.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
CAPR Address
CAPR
 
CAPR Latest News
 
Your Comments and Response on Capricor Therapeutics Inc
 
CAPR Business Profile
Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in preclinical stage for the potential prevention of COVID-19. Capricor collaborates with Lonza Houston, Inc. for the development of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California. Address: 8840 Wilshire Boulevard, Beverly Hills, CA, United States, 90211
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service